EVGN - Evogene Ltd.
IEX Last Trade
1.73
0 0%
Share volume: 1,072
Last Updated: Fri 27 Dec 2024 04:38:37 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.73
0.00
0.00%
Fundamental analysis
5%
Profitability
0%
Dept financing
5%
Liquidity
50%
Performance
0%
Performance
5 Days
25.19%
1 Month
0.18%
3 Months
-33.98%
6 Months
144.93%
1 Year
100.12%
2 Year
150.30%
Key data
Stock price
$1.73
DAY RANGE
$1.51 - $1.72
52 WEEK RANGE
$0.59 - $6.30
52 WEEK CHANGE
$101.19
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/21/2024
Company detail
CEO: Ofer Haviv
Region: US
Website: evogene.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: evogene.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Evogene Ltd. focuses on product discovery and development in multiple life-science based industries, including human health and agriculture. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer.
Recent news